What’s the current market cap for Sana Biotechnology stock?

Sana Biotechnology (SANA) has a market cap of $746m as of June 07, 2026.

What is the P/E ratio for Sana Biotechnology stock?

The price to earnings (P/E) ratio for Sana Biotechnology (SANA) stock is 0 as of June 07, 2026.

Does Sana Biotechnology stock pay dividends?

No, Sana Biotechnology (SANA) stock does not pay dividends to its shareholders as of June 07, 2026.

When is the next Sana Biotechnology dividend payment date?

Sana Biotechnology (SANA) stock does not pay dividends to its shareholders.

What is the beta indicator for Sana Biotechnology?

Sana Biotechnology (SANA) has a beta rating of 2.18. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Sana Biotechnology stock | $SANA Share Price

13:30

15:10

16:45

18:25

20:00

About Sana Biotechnology

Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.

Ticker

$SANA

Sector

Health

Primary listing

NASDAQ

Employees

142

Headquarters

Seattle, United States

Website

www.sana.com

SANA Metrics

BasicAdvanced

$746m

-$0.92

2.18

What the Analysts think about SANA

Analyst ratings (Buy, Hold, Sell) for Sana Biotechnology stock.

Bulls say / Bears say

A strategic collaboration with Mayo Clinic for SC451 includes a $25 million equity investment and an option for another $25 million, accelerating the development of its hypoimmune islet cell therapy with a planned Phase 1 trial later this year (Reuters, GlobeNewswire).

An investigator-sponsored 14-month follow-up of UP421 demonstrated sustained survival and function of transplanted hypoimmune pancreatic beta cells, with stable C-peptide production and no safety issues, supporting the platform’s potential as a functional cure for type 1 diabetes (GlobeNewswire, Reuters).

The company raised $69 million through an at-the-market facility and secured a $25 million investment from Mayo Clinic, bringing pro forma cash to $128.9 million and extending its cash runway into mid-2027 to fund R&D and planned IND submissions (Reuters, GlobeNewswire).

Q1 2026 GAAP net loss was $47.2 million or $0.17 per share, with non-GAAP operating cash burn at $37.0 million. Cash balances dropped by $37.3 million to $101.1 million, highlighting the company’s substantial cash burn and ongoing funding requirements (GlobeNewswire).

The reduction in R&D expenses was partly due to suspending allogeneic CAR T programs, which may limit Sana’s pipeline diversity and future growth potential in oncology (GlobeNewswire).

SANA shares have fallen about 24% year-to-date to around $3.09, showing investor caution and valuation concerns as the market waits for key clinical trial results (Reuters).

Data summarised monthly by Lightyear AI. Last updated on 21 May 2026.

SANA Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

SANA Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SANA

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

The reduction in R&D expenses was partly due to suspending allogeneic CAR T programs, which may limit Sana’s pipeline diversity and future growth potential in oncology (GlobeNewswire).

SANA shares have fallen about 24% year-to-date to around $3.09, showing investor caution and valuation concerns as the market waits for key clinical trial results (Reuters).

Data summarised monthly by Lightyear AI. Last updated on 21 May 2026.

About Sana Biotechnology

Ticker

Employees

SANA Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about SANA

Analyst Ratings

Bulls say / Bears say

SANA Financial Performance

Income Statement

SANA Earnings Performance

Earnings per share (EPS)

Buy $SANA

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Sana Biotechnology/$SANA

About Sana Biotechnology

Ticker

Employees

SANA Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about SANA

Analyst Ratings

Bulls say / Bears say

SANA Financial Performance

Income Statement

SANA Earnings Performance

Earnings per share (EPS)

Buy $SANA

Upcoming events

No upcoming events

What’s the current market cap for Sana Biotechnology stock?

What is the P/E ratio for Sana Biotechnology stock?

Does Sana Biotechnology stock pay dividends?

When is the next Sana Biotechnology dividend payment date?

What is the beta indicator for Sana Biotechnology?

Bulls say / Bears say